Bristol-Myers Squibb Statement on Resignation of Dr. José Baselga

Friday, September 14, 2018 5:23 pm EDT

Dateline:

NEW YORK, NY

NEW YORK, September 14, 2018 – Today, José Baselga, M.D., Ph.D. resigned from the Board of Directors of Bristol-Myers Squibb Company  (NYSE: BMY) (the “Company”).  The size of the Company’s Board of Directors was decreased to eleven, effective immediately, in connection with Dr. Baselga’s resignation.

Bristol-Myers Squibb is committed to the highest standards of ethics, compliance and integrity. These principles are central to the Company’s mission and our ability to deliver innovative medicines to patients with serious disease.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit us at BMS.com or follow us on  LinkedIn, Twitter, YouTube and Facebook.

###

Contacts

Media:

Laura Hortas, 609-252-4587, laura.hortas@bms.com

Lisa McCormick Lavery, 609-252-7602, lisa.mccormicklavery@bms.com

Investors:

Tim Power, 609-252-7509, timothy.power@bms.com

Bill Szablewski, 609-252-5894, william.szablewski@bms.com

Privacy Policy
Business Wire NewsHQsm